Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
MarketBeat

MYSTERIOUS: Caredx sharpens precision diagnostics push with naveris deal alloheme plans - You Need To See This

CareDx (NASDAQ:CDNA) executives outlined the company’s strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion.

Chief Executive Officer John Hanna said CareDx has reshaped its portfolio around areas where it believes it has core strengths: building clinical adoption of molecular testing, supporting repeat testing workflows and generating evidence to support reimbursement. He said those priorities led the company to divest its lab products business, accelerate its AlloHeme pipeline program and pursue the acquisition of Naveris, a company focused on viral-mediated cancers.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.